Physician profile
Ray A Lebeda
NPI 1619933397
$21,257.76
in general payments reported to CMS, 2019-2025
58 companies · $3,445 in 2025
The $3,445 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $2,246 · 2021: $2,998 · 2022: $2,866 · 2023: $3,816 · 2024: $3,481 · 2025: $3,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,658.18 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,000.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,544.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,499.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,668.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,365.74 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,024.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $890.37 | 2019-2025 | Prolia, Evenity, Repatha |
| Abbott Laboratories | $750.21 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $729.30 | 2022-2025 | |
| Amarin Pharma, INC. | $641.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $580.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $504.09 | 2019-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.21 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $419.96 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $400.37 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Lebeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.